NCT00758225View on ClinicalTrials.gov

Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Idebenone

Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients \> 45 kg: 900 mg/day (2 tablets 3 times a day)

Trial Locations (1)

3000

University Hospitals Leuven, Leuven

Sponsors
All Listed Sponsors
lead

Santhera Pharmaceuticals

INDUSTRY

NCT00758225 - Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension) | Biotech Hunter | Biotech Hunter